Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study by Arshad, Samia et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Infectious Diseases Articles Infectious Diseases 
4-1-2017 
Ceftaroline fosamil monotherapy for methicillin-resistant 
Staphylococcus aureus bacteremia: a comparative clinical 
outcomes study. 
Samia Arshad 
Henry Ford Health System, sarshad1@hfhs.org 
Vanthida Huang 
Pamela Hartman 
Henry Ford Health System 
Mary Perri 
Henry Ford Health System, MPERRI1@hfhs.org 
Daniela Moreno 
Henry Ford Health System 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/
infectiousdiseases_articles 
Recommended Citation 
Arshad S, Huang V, Hartman P, Perri MB, Moreno D, and Zervos MJ. Ceftaroline fosamil monotherapy for 
methicillin-resistant Staphylococcus aureus bacteremia (MRSAB): A comparative clinical outcomes study. 
Int J Infect Dis 2017; 57:27-31. 
This Article is brought to you for free and open access by the Infectious Diseases at Henry Ford Health System 
Scholarly Commons. It has been accepted for inclusion in Infectious Diseases Articles by an authorized 
administrator of Henry Ford Health System Scholarly Commons. 
Authors 
Samia Arshad, Vanthida Huang, Pamela Hartman, Mary Perri, Daniela Moreno, and Marcus J. Zervos 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
infectiousdiseases_articles/30 
Ceftaroline fosamil monotherapy for methicillin-resistant
Staphylococcus aureus bacteremia: a comparative clinical outcomes
study
Samia Arshada,*, Vanthida Huangb, Pamela Hartmana, Mary B. Perria, Daniela Morenoa,
Marcus J. Zervosa,c
aDivision of Infectious Diseases, Henry Ford Hospital, 2799 West Grand Blvd, CFP 314, Detroit, MI 48202, USA
bMidwestern University College of Pharmacy–Glendale, Glendale, Arizona, USA
cWayne State University, School of Medicine, Detroit, Michigan, USA
A R T I C L E I N F O
Article history:
Received 19 October 2016
Received in revised form 13 January 2017
Accepted 18 January 2017







S U M M A R Y
Objectives: Vancomycin is the treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA)
bacteremia; however, its use has been subject to scrutiny due to failure in severe infections. Ceftaroline
fosamil (CPT-F) is approved for MRSA acute bacterial skin and skin structure infections, but not for
bloodstream infections. The clinical outcomes of treatment with CPT-F in patients with MRSA bacteremia
were evaluated.
Methods: Patients diagnosed with MRSA bacteremia at Henry Ford Hospital in Detroit, Michigan, USA,
involving isolates with a vancomycin minimum inhibitory concentration 1.0 mg/l and susceptible in
vitro to CPT-F, were systematically reviewed retrospectively. Ceftaroline fosamil-treated patients were
matched with at least two vancomycin- and/or one daptomycin-treated control patient based on age-
patients age 65 years or greater or less than 65 years of age. Outcomes evaluated included the duration of
hospitalization, duration of therapy, adverse events, relapse, hospital readmission, and death.
Results: Thirty consecutive cases of MRSA bacteremia treated with CPT-F during the period May 2011 to
June 2013 were identified; these patients were matched to 56 MRSA bacteremia patients treated with
vancomycin and 46 MRSA bacteremia patients treated with daptomycin. The primary source of MRSA
bacteremia in the cohort treated with CPT-F was endocarditis (n = 7, 23%), skin/wound (n = 9, 30%), and
bone/joint (n = 8, 27%). The MRSA bacteremia in those treated with CPT-F was community-acquired in
43% of cases, healthcare-associated in 43%, and hospital-acquired in 13%. The mean length of hospital stay
for these patients was 22 days. The overall 30-day mortality rate was 13% (n = 4) in CPT-F patients versus
24% (n = 11) in daptomycin patients and 11% (n = 6) in vancomycin patients (p = 0.188).
Conclusions: CPT-F demonstrated comparable clinical outcomes in MRSA bacteremia patients compared
with the other agents, especially as salvage therapy.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) blood-
stream infections (BSI) continue to have high mortality, with
rates of 20–30% reported in recent studies.1 According to the US
Centers for Disease Control and Prevention (CDC), an attributable
94 360 invasive infections and 18 650 deaths occur annually in the
USA.2 Due to the high rates of mortality, an improvement in the
outcomes through better safety and efficacy of treatment, a
reduction in infection rates, and better prevention measures to
decrease readmission rates and hospitalization costs is required.
The initial treatment of choice for serious MRSA infections is
vancomycin.3,4 However, there have been increasing reports of
vancomycin failures and failures attributed to elevated vancomycin
minimum inhibitory concentrations (MICs).5 Consensus guidelines
recommend the consideration of alternative agents in this
setting3,6; thus, optimal therapeutic options for serious MRSA
infections remain to be determined.3
Ceftaroline fosamil (CPT-F) is a novel cephalosporin approved
by the US Food and Drug Administration (FDA) for the treatment of* Corresponding author. Tel.: +1 917 449 3734; fax: +1 313 916 2993.
E-mail address: sarshad1@hfhs.org (S. Arshad).
http://dx.doi.org/10.1016/j.ijid.2017.01.019
1201-9712/© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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acute bacterial skin and skin structure infections caused by MRSA
and for community-acquired bacterial pneumonia.7 Ceftaroline 
the active metabolite of the prodrug CPT-F  has been used for the
treatment of serious infections, and case observations have been
reported.8–11 However, there are no data from studies that have
evaluated comparative outcomes with this approach, and there is
minimal evidence for the use of ceftaroline therapy for strains with
vancomycin heteroresistance, reduced in vitro susceptibility
within the susceptible range, or in patients who have failed
treatment with or are intolerant to vancomycin. To date, the role of
ceftaroline in the treatment of severe MRSA infections has not been
evaluated. Therefore, this study was performed to evaluate CPT-F
as monotherapy versus daptomycin and vancomycin in the
treatment of MRSA bacteremia caused by strains with vancomycin
MICs of 1.0 mg/l.
Methods
This was a retrospective matched cohort study conducted at
Henry Ford Hospital in Detroit, Michigan, USA, which was
approved by the hospital institutional review board. Patients aged
18 years who had been diagnosed with MRSA bacteremia, with a
vancomycin MIC 1.0 mg/l and susceptible to CPT-F, between
November 2009 and December 2013, were identified. The selection
of antibiotics was made at the discretion of the infectious disease
(ID) physicians caring for the patient.
Patients treated with CPT-F were matched with two control
patients treated with vancomycin and two control patients treated
with daptomycin based on age (65 years), intensive care unit
(ICU) status during MRSA bacteremia-related admission, and
severity of illness. Severity was defined by the source of the BSI,
which was classified into one of three categories: low-risk sources
(related mortality rate <10%), which included intravenous cathe-
ter, urinary tract, ear–nose–larynx, gynecological sources, and
several manipulation-related sources; intermediate-risk sources
(associated mortality rate 10–20%), which included osteoarticular,
soft tissue, and unknown sources; and high-risk sources (mortality
rate >20%), which included endovascular, lower respiratory tract,
abdominal, and central nervous system foci, as described
previously.12,13
Demographic information and outcome measures collected
included the duration of hospitalization and therapy, adverse
events, 42-day relapse, 30-day hospital readmission, and 30-day
mortality from onset of infection.
The initial identification of isolates and susceptibility testing
(Vitek 2; bioMérieux, Inc., Durham, NC, USA) was performed by the
clinical microbiology laboratory. The MICs for CPT-F, daptomycin,
and vancomycin were determined for all isolates utilizing
epsilometer tests (Etest; bioMérieux, Durham, NC, USA), which
were performed in accordance with the manufacturer’s instruc-
tions. The MICs for vancomycin were also determined for all
isolates by broth microdilution, according to Clinical and
Laboratory Standards Institute (CLSI) guidelines.14 Isolates were
screened for heteroresistance to vancomycin using the macro-
dilution method Etest (AB Biodisk, Solna, Sweden).15
A sample size collection of charts was estimated from a total of
150 patients who were hospitalized with MRSA bacteremia during
the study period, with approximately 30 patients (20%) treated
with ceftaroline and 120 patients (80%) treated with other
therapeutic agents. Patients treated with ceftaroline versus
vancomycin or daptomycin were matched 1:4 to yield a sufficient
sample size for comparative analysis, using a two-sided signifi-
cance level for a of 0.05 and 80% power.
Patient demographics were evaluated using descriptive statis-
tics. Categorical variables were compared using the Chi-square test
or Fisher’s exact test when the sample size was small. Continuous
variables were compared using the two-sample t-test. Conditional
logistic regression modeling was used throughout to account for
the case–control matching. A p-value of <0.05 was considered
statistically significant. All data were analyzed using both IBM SPSS
Statistics version 20.0 (IBM Corp., Armonk, NY, USA) and SAS
software version 9.2 (SAS Institute Inc, Cary, NC, USA). The primary
outcome was composite failure defined as the presence of any of
the three main efficacy endpoints: mortality within 30 days from
onset of infection, infection relapse within 42 days, or readmission
within 30 days after the end of treatment.
Results
From a total 132 patients, 30 consecutive cases of MRSA
bacteremia treated with CPT-F were identified during the period
May 2011 to December 2013. The matched control group consisted
of 102 MRSA bacteremia patients: 46 treated with daptomycin and
56 treated with vancomycin during the period November 2009 to
May 2013. Baseline demographic information for all three
treatment groups is shown in Table 1.
The baseline demographic characteristics were similar in the
three treatment groups. However, patients treated with CPT-F had
a longer duration of bacteremia (p = 0.075) than the other two
cohorts; this may be attributable to more than half of the
ceftaroline patients (n = 17, 57%) initially failing standard treatment
and consequently being switched to CPT-F due to a documented
poor clinical response, per the consulting ID physician. The origin
of the MRSA bacteremia for patients treated with CPT-F versus
those treated with the standard of care was 43% vs. 61%
community-acquired, 43% vs. 34% healthcare-associated, and
13% vs. 6% hospital-acquired, respectively. Overall, mortality
within 30 days from onset of infection was observed in 13.3% of
patients treated with CPT-F, 24% of those treated with daptomycin,
and 11% of those treated with vancomycin (p = 0.188). In the group
treated with CPT-F, three of four patients who died were
endocarditis bacteremia patients and two had left-sided endocar-
ditis with an APACHE II score of 15–20 points.
Tables 2 and 3 show the univariable and multivariable logistic
regression results for the composite failure outcome. The results
indicate that treatment with CPT-F was not significantly associated
(either univariably or multivariably) with composite failure
(mortality/relapse/readmission). The composite failure outcome
was seen in seven of 30 CPT-F patients (23.3%) and 22 of 102 non-
CPT-F patients (21.6%); this difference was not statistically
significant (p = 0.837).
Patient-related factors associated with composite failure
were African American race (p = 0.026, odds ratio (OR) 7.1) and
chronic obstructive pulmonary disease (COPD) (p = 0.038, OR 6.4)
(Table 3).
The duration of intravenous therapy for all patients was 4–8
weeks. All but one of the patients treated with CPT-F had
microbiological cure at the end of treatment (97%). Susceptibility
testing results for the CPT-F group were as follows: the vancomycin
MIC90 was 1.7 mg/l by Etest; the mean vancomycin MIC was
1.13 mg/l by automated test (Vitek 2; bioMérieux, Inc., Durham, NC,
USA); the mean daptomycin MIC was 0.52 mg/l and CPT-F MIC was
0.65 mg/l by Etest. For the control group, the vancomycin MIC90
was 1.6 mg/l by Etest and 1.06 mg/l by Vitek. The mean MICs for
CPT-F and daptomycin were 0.62 mg/l and 0.52 mg/l, respectively,
with one isolate that was intermediate-susceptible to CPT-F with a
MIC of 1.5 mg/l. None of the isolates in either treatment group
demonstrated heteroresistance to vancomycin. All susceptibilities
were performed on all isolates with vancomycin utilizing the Etest,
Vitek 2, and manual broth microdilution methods, while CPT-F and
daptomycin MICs were performed using only the Etest.
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Discussion
The treatment of choice for MRSA bacteremia for over four
decades, since its discovery, has been vancomycin. However, in
recent decades there have been increasing reports of vancomycin
failure in patients with serious MRSA infections, such as
bacteremia and infective endocarditis.12,13 Furthermore, the
reporting of increasing vancomycin MICs poses a challenge for
clinicians in maximizing the pharmacodynamic parameters of
vancomycin to achieve the appropriate treatment dose for these
infections.3,4,12,13
The optimal management of MRSA bacteremia is uncertain. The
Infectious Diseases Society of America (IDSA) currently recom-
mends trough serum levels of vancomycin of 15–20 mg/l for
serious infections.3 These trough serum levels, however, have not
been shown to be safe, with an associated risk of nephrotoxicity
reported in recent studies.16,17 Nephrotoxicity, recurrence of
infection, microbiological failure, and mortality must be consid-
ered in the selection and overall clinical success of therapy.
Therefore, recommendations have been made for the consider-
ation of alternative agents, although most of the alternative agents
do not have FDA indications for use in these serious infections,
which has proven a challenge for clinicians.
Table 2
Univariable logistic regression results for the composite failure outcome (30-day mortality/42-day relapse/30-day readmission).
Variable p-Value OR 95% CI
Ceftaroline treatment 0.623 1.295 0.463–3.621
Age 0.118 1.041 0.990–1.094
Male sex 0.615 0.772 0.282–2.116
African American race 0.156 2.485 0.707–8.738
APACHE II 0.919 0.995 0.903–1.097
Previous hospitalization 90 days from onset of infection 0.680 0.818 0.315–2.124
Staphylococcus aureus infection 1 year prior to admission 0.143 0.356 0.089–1.419
Source of bacteremia
Endocarditis 0.580 0.584 0.087–3.914
Bone/joint 0.178 0.367 0.086–1.575
Skin/wound 0.201 2.519 0.611–10.376
Cancer 0.754 0.794 0.187–3.366
HIV 0.485 2.062 0.270–15.749
Diabetes 0.548 0.733 0.266–2.021
Liver disease 0.495 1.538 0.446–5.306
IV drug user 0.768 0.823 0.226–2.998
Acute renal failure 0.202 2.182 0.658–7.241
Congestive heart failure 0.729 1.218 0.398–3.726
Vascular disease 0.732 1.338 0.252–7.100
COPD 0.056 3.652 0.970–13.753
OR, odds ratio; CI, confidence interval; APACHE II, Acute Physiology and Chronic Health Evaluation II; IV, intravenous; COPD, chronic obstructive pulmonary disease.
Table 1








Age, years Number 30 46 56 0.721
Mean (SD) 55.9 (12.7) 53.5 (15.4) 54.9 (16.7)
Sex, n (%) Female 13 (43%) 23 (50%) 24 (43%) 0.745
Male 17 (57%) 23 (50%) 32 (57%)
Race, n (%) African American 16 (57%) 30 (68%) 35 (69%) 0.439
Caucasian 9 (32%) 13 (30%) 15 (29%)
Other 3 (11%) 1 (2%) 1 (2%)
APACHE II score Number 30 46 56 0.978
Mean (SD) 11.8 (4.7) 12.2 (5.7) 11.8 (5.3)
Previous hospitalization 90 days from onset of infection, n (%) 15 (50%) 28 (61%) 28 (50%) 0.491
Staphylococcus aureus infection 1 year prior to admission, n (%) 9 (30%) 10 (22%) 8 (14%) 0.219
Source of bacteremia, n (%)
Endocarditis 7 (23%) 19 (41%) 13 (23%) 0.096
Bone/joint 8 (27%) 10 (22%) 9 (16%) 0.492
Skin/wound 9 (30%) 10 (22%) 15 (27%) 0.704
ICU ever during admission, n (%) 12 (40%) 27 (59%) 20 (36%) 0.057
Cancer, n (%) 2 (7%) 5 (11%) 6 (11%) 0.867
HIV, n (%) 2 (7%) 2 (4%) 4 (7%) 0.810
Diabetes mellitus, n (%) 16 (53%) 16 (35%) 19 (34%) 0.170
Liver disease, n (%) 7 (23%) 12 (26%) 13 (23%) 0.937
IV drug user, n (%) 7 (23%) 16 (35%) 12 (21%) 0.285
Acute renal failure, n (%) 8 (27%) 11 (24%) 7 (13%) 0.195
Congestive heart failure, n (%) 5 (17%) 11 (24%) 6 (11%) 0.205
Vascular disease, n (%) 3 (10%) 4 (9%) 9 (16%) 0.483
COPD, n (%) 4 (13%) 5 (11%) 7 (13%) 0.943
Clinical outcomes, n (%)
30-day mortality 4 (14%) 11 (24%) 6 (11%) 0.188
42-day relapse 2 (7%) 1 (2%) 1 (2%) 0.443
30-day readmission 2 (7%) 3 (7%) 3 (5%) 1.000
MRSA, methicillin-resistant Staphylococcus aureus; SD, standard deviation; APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; IV,
intravenous; COPD, chronic obstructive pulmonary disease.
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Daptomycin is recommended as an alternative for the
treatment of MRSA bacteremia in the IDSA guidelines. In 2012,
Moore et al. demonstrated that daptomycin was associated with
better outcomes than vancomycin in the treatment of MRSA
bacteremia with higher vancomycin MICs (defined as a MIC >1 mg/
l).18 A year later, Murray et al. demonstrated that an early switch to
daptomycin compared to vancomycin for the treatment of MRSA
bacteremia with a vancomycin MIC >1 mg/l significantly improved
outcomes.19 In addition, they showed a decrease in 30-day
mortality with daptomycin (20.0% vs. 48.2%; p < 0.001). However,
in 2011, van Hal et al. reported daptomycin resistance in a
daptomycin-naïve patient and the need for optimal management
in such cases.20 Investigators have shown the benefit of combina-
tion therapy with the addition of a b-lactam antibiotic such as CPT-
F to daptomycin versus daptomycin monotherapy in preventing
daptomycin resistance and sustaining killing in the treatment of
MRSA bacteremia.20–22 Cunha et al. also reported a case of
daptomycin resistance in an acute bacterial endocarditis patient
following a week of vancomycin therapy for MRSA bacteremia,
who subsequently died.23 A randomized controlled trial compar-
ing daptomycin vs. vancomycin for the treatment of MRSA
bacteremia with a high vancomycin MIC (defined as 1 mg/l)
remains ongoing.24 The experience of the present authors along
with the data reported in previously published studies demon-
strates inconsistent results for daptomycin therapy in MRSA
bacteremia with an elevated vancomycin MIC.4,25
There is a paucity of data in the previous literature on the use of
CPT-F in the treatment of MRSA bacteremia. A case series of 10
patients reported by Lin et al. found CPT-F to treat severe MRSA
infections effectively, with a microbiological cure rate of 70%.10
There are seven recent reports of studies that have investigated the
utility of CPT-F in serious MRSA infections in patients who have not
responded to standard therapy.8–11,26 The largest study was a
multicenter retrospective evaluation of the efficacy and safety of
CPT-F in which Casapao et al. evaluated 527 patients who received
CPT-F for at least 72 h.26 Bacteremia was noted in 28% (148/527) of
the patients and CPT-F was prescribed after approximately 6 days
of vancomycin or daptomycin therapy. Ceftaroline was most often
used in the treatment of S. aureus infections, especially BSI.
The present study demonstrated that CPT-F is not inferior to the
standard treatment for patients with MRSA bacteremia. Approxi-
mately 90% of patients treated with CPT-F for MRSA bacteremia
survived, despite the difficulties associated with treatment options
for MRSA, an increasingly resistant pathogen. A high prevalence of
left-sided infective endocarditis was found in the cohort treated
with CPT-F (27%), which is an independent risk factor associated
with mortality. The patients treated with CPT-F had a longer
duration of bacteremia (p = 0.0053) than the control group
patients, which is likely due to the use of ceftaroline for patients
with refractory MRSA BSI and alteration from standard therapy to
CPT-F; this is in agreement with the findings of Polenakovik and
Pleiman8 and Casapao et al.26
The limitations of this study include its retrospective design and
single-center setting. The strengths include the consecutive
patient and strain selection and the large sample size for off-
label use, and the study is unique in providing strong, comparative
matching criteria for each CPT-F-treated patient.
In conclusion, CPT-F was found to be efficacious in the
treatment of serious infections due to MRSA, as well as S. aureus
strains with reduced susceptibility to vancomycin and non-
susceptibility to daptomycin. MRSA bacteremia infections are
complex; this was highlighted by the group of patients who failed
on standard therapy with vancomycin and daptomycin and
subsequently responded to treatment with CPT-F. Ceftaroline is
a safe antimicrobial. Nevertheless, clinicians should be cautious of
hematological toxicity and the possibility of eosinophilic pneumo-
nia when CPT-F is used in the long term ( > 14 days).27 The use of
ceftaroline in the future for serious infections warrants its
investigation as monotherapy versus combination therapy in a
randomized trial to optimize its role as a therapeutic option.
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